CN115590941A - Traditional Chinese medicine composition and application thereof in preparation of medicine for treating acute ischemic stroke - Google Patents
Traditional Chinese medicine composition and application thereof in preparation of medicine for treating acute ischemic stroke Download PDFInfo
- Publication number
- CN115590941A CN115590941A CN202211082031.7A CN202211082031A CN115590941A CN 115590941 A CN115590941 A CN 115590941A CN 202211082031 A CN202211082031 A CN 202211082031A CN 115590941 A CN115590941 A CN 115590941A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- medicine composition
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 208000032382 Ischaemic stroke Diseases 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 claims abstract description 15
- 208000026435 phlegm Diseases 0.000 claims abstract description 15
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 9
- 241000885743 Melastoma dodecandrum Species 0.000 claims abstract description 9
- 241001522129 Pinellia Species 0.000 claims abstract description 9
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 241001080798 Polygala tenuifolia Species 0.000 claims abstract description 8
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 7
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims description 35
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 4
- 230000003959 neuroinflammation Effects 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 abstract description 23
- 206010056292 Androgen-Insensitivity Syndrome Diseases 0.000 abstract description 16
- 230000002757 inflammatory effect Effects 0.000 abstract description 13
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract description 10
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 8
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 8
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 8
- 230000006870 function Effects 0.000 abstract description 8
- 210000005013 brain tissue Anatomy 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000004393 prognosis Methods 0.000 abstract description 6
- 206010021143 Hypoxia Diseases 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 208000028867 ischemia Diseases 0.000 abstract description 5
- 210000005036 nerve Anatomy 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 230000007954 hypoxia Effects 0.000 abstract description 4
- 230000000451 tissue damage Effects 0.000 abstract description 4
- 231100000827 tissue damage Toxicity 0.000 abstract description 4
- 241000721047 Danaus plexippus Species 0.000 abstract description 3
- 235000003143 Panax notoginseng Nutrition 0.000 abstract description 2
- 241000180649 Panax notoginseng Species 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 11
- 230000002490 cerebral effect Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000000302 ischemic effect Effects 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- NGMYNFJANBHLKA-SENBMHEBSA-N Icariside II Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O)c(C/C=C(\C)/C)c3O2)cc1 NGMYNFJANBHLKA-SENBMHEBSA-N 0.000 description 4
- NGMYNFJANBHLKA-LVKFHIPRSA-N icariside II Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O)C(CC=C(C)C)=C2O1 NGMYNFJANBHLKA-LVKFHIPRSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000014604 Specific Language disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition and application thereof in preparing a medicine for treating acute ischemic stroke. The traditional Chinese medicine composition comprises, by mass, 15-25 parts of melastoma dodecandrum, 7-12 parts of pinellia ternate, 3-9 parts of exocarpium citri rubrum, 10-20 parts of radix curcumae, 9-15 parts of pseudo-ginseng, 9-15 parts of ligusticum wallichii, 5-15 parts of polygala tenuifolia and 9-15 parts of rhizoma acori graminei. The invention takes the melastoma dodecandrum and the pinellia ternate as monarch drugs, takes the exocarpium citri rubrum, the ligusticum wallichii and the panax notoginseng as auxiliary drugs, has the functions of promoting blood circulation, reducing phlegm and dredging collaterals, and achieves the effects of reducing phlegm and removing blood stasis, and inducing resuscitation and restoring consciousness by combining the whole formula; the traditional Chinese medicine composition can relieve tissue damage of brain tissues in hypoxia and ischemia by inhibiting the release of inflammatory factors such as TNF-alpha, IL-1 beta, IL-6 and the like, thereby promoting the recovery of the nerve function of patients, improving the independent life capacity after stroke, finally improving the prognosis of AIS patients, playing a positive role in reducing disability rate, and being worthy of clinical popularization.
Description
Technical Field
The invention belongs to the technical field of cerebral apoplexy treatment, and particularly relates to a traditional Chinese medicine composition and application thereof in preparation of a medicine for treating acute ischemic cerebral apoplexy.
Background
The cerebral apoplexy is the main cause of death of Chinese people, the death of the cerebral apoplexy accounts for one third of the world, and becomes the first disabling disease species in China, and the ischemic cerebral apoplexy accounts for 69.6 percent of all patients with the cerebral apoplexy. With the advance of the aging process of the population in China, the reduction of the disability rate and the death rate of cerebral apoplexy faces a great challenge.
The pathological nature of AIS is that intravascular thrombosis causes ischemic damage and even necrosis of the brain tissue in its innervated area. Therefore, the AIS patients within the time window are treated by direct recanalization through thrombolysis, vascular intervention thrombus extraction and the like clinically, and good prognosis is obtained, but the measures for recanalization of blood vessels of the AIS patients outside the time window are quite limited. Normative stroke management can reduce post-stroke complications, but damage to ischemic brain tissue and neuronal death cannot be completely avoided.
The mechanism of neuronal damage caused by ischemia is complex, mainly characterized by excitotoxicity, calcium overload, and oxidative stress in the early stage, and neuroinflammation and apoptosis in the later stage. Therefore, the multi-target intervention can be carried out through different action mechanisms of the medicine, and a new treatment idea is provided for the treatment of the stroke. The ischemic brain tissue initiates neuroinflammation by inducing inflammatory factors such as TNF-alpha, IL-1 beta, IL-6 and the like, thereby promoting the destruction of blood brain barrier, causing edema, hemorrhage and the like of nerve cells, and aggravating the apoptosis of neuron cells. Therefore, the damage to ischemic tissues of stroke patients can be reduced by reducing local inflammatory factors (such as TNF-alpha, IL-1 beta, IL-6 and the like). Therefore, the key points of promoting the recovery of the stroke nerve function are to recover the hypoxia injury of ischemic tissues and inhibit the release of inflammatory mediators in the early stage of AIS and reduce local inflammation.
For example, the application of the Chinese patent application with the publication number of CN103989696A discloses the application of the baohuoside I in preparing the medicine for preventing and treating the cerebral arterial thrombosis, and the research shows that the baohuoside I has the protection effect on a Lipopolysaccharide (LPS) lateral ventricle injection induced AD-like rat model, and the mechanism of the baohuoside I is related to the over-expression of the baohuoside I in inhibiting inflammatory factor cyclooxygenase 2 (COX-2), interleukin 1 beta (IL-1 beta), inducible nitric oxide synthase iNOS and the like induced by the LPS.
The exploration and development of more medicaments with therapeutic action on the acute ischemic stroke have important significance.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition and application thereof in preparing a medicine for treating acute ischemic stroke.
In order to achieve the purpose, the technical scheme of the invention is as follows:
a traditional Chinese medicine composition comprises, by mass, 15-25 parts of melastoma dodecandrum, 7-12 parts of pinellia ternate, 3-9 parts of exocarpium citri rubrum, 10-20 parts of radix curcumae, 9-15 parts of pseudo-ginseng, 9-15 parts of ligusticum wallichii, 5-15 parts of polygala tenuifolia and 9-15 parts of rhizoma acori graminei.
The AIS belongs to the categories of 'apoplexy', 'wind bias', 'body bias' and the like in traditional Chinese medicine, pathological factors are not wind-fire phlegm stasis, congenital deficiency, spleen failure and transportation caused by improper diet or excessive desire, dampness accumulation and phlegm generation, wind-phlegm upper disturbance and internal resistance, collateral channel fleeing, upper obstruction and orifice clearing, and skin numbness and hand-foot numbness are seen; the symptoms of hemiplegia, slurred speech, facial distortion, etc. are caused by the deficiency of the meridians, pathogenic wind in the body and obstruction of qi and blood.
The research of the invention finds that the apoplexy patients are mostly suffered from phlegm-stasis orifices obstruction, and the apoplexy is caused by obstruction of qi and blood circulation, phlegm-stasis accumulation and blood vessel obstruction. Therefore, the melastoma dodecandrum and the pinellia ternate are used as monarch drugs, the exocarpium citri rubrum, the ligusticum wallichii and the pseudo-ginseng are used as auxiliary drugs, the blood circulation promoting, phlegm eliminating and collaterals dredging are performed, the rhizoma acori graminei, the radix curcumae and the polygala tenuifolia are used for restoring consciousness and inducing resuscitation, and the effects of reducing phlegm and removing blood stasis and inducing resuscitation are achieved together; when the traditional Chinese medicine composition is used for treating AIS patients with phlegm stagnation and orifice obstruction, the Chinese medicine symptom score is obviously lower than that of a conventional treatment group after 2 weeks of continuous treatment.
Meanwhile, the traditional Chinese medicine composition is researched and found to reduce the tissue damage of brain tissues in hypoxia and ischemia by inhibiting the release of inflammatory factors such as TNF-alpha, IL-1 beta, IL-6 and the like, so that the nerve function rehabilitation of patients is promoted, the life independence ability after stroke is improved, the prognosis of AIS patients is finally improved, the positive effect on reducing disability rate is achieved, and the clinical popularization is worthy of being realized.
Based on the above, the invention also provides application of the traditional Chinese medicine composition in preparation of a medicine for treating acute ischemic stroke, and preferably, the acute ischemic stroke is phlegm stagnation type acute ischemic stroke.
Meanwhile, the invention also provides application of the traditional Chinese medicine composition in preparing medicines for treating neuroinflammation.
Preferably, the traditional Chinese medicine composition comprises, by mass, 20 parts of melastoma dodecandrum, 9 parts of pinellia ternate, 6 parts of exocarpium citri rubrum, 15 parts of radix curcumae, 12 parts of pseudo-ginseng, 12 parts of ligusticum wallichii, 10 parts of polygala tenuifolia and 12 parts of rhizoma acori graminei.
Compared with the prior art, the invention has the beneficial effects that:
(1) The traditional Chinese medicine composition takes the melastoma dodecandrum and the pinellia ternate as monarch drugs, is supplemented with the exocarpium citri rubrum, the ligusticum wallichii and the panax notoginseng for promoting blood circulation, reducing phlegm and dredging collaterals, and the rhizoma acori graminei, the radix curcumae and the polygala tenuifolia for restoring consciousness and inducing resuscitation; when the traditional Chinese medicine composition is used for treating the phlegm stasis type AIS patients, the Chinese medicine symptom integral after 2 weeks of continuous treatment is obviously lower than that of the conventional treatment group.
(2) The traditional Chinese medicine composition can relieve the tissue damage of brain tissues in hypoxia and ischemia by inhibiting the release of inflammatory factors such as TNF-alpha, IL-1 beta, IL-6 and the like, thereby promoting the nerve function rehabilitation of patients, improving the independent life capacity after stroke, finally improving the prognosis of AIS patients, playing a positive role in reducing disability rate, and being worthy of clinical popularization.
Drawings
Fig. 1 is a statistical chart of the modified Rakin scale scores of AIS patients on day 90 after treatment with the traditional Chinese medicine composition of the present invention;
wherein the modified Rankin scale scores in the range of 0 to 6, with no symptoms (score 0), no clinically significant disability (score 1), mild disability (score 2), moderate disability (score 3), moderate severe disability (score 4), severe disability (score 5), death (score 6).
Detailed Description
The technical scheme of the invention is further explained in detail by combining the attached drawings and the detailed description.
In the embodiment of the invention, SPSS26.0 statistical software is adopted to process data, and normal distribution measurement data is in mean plus or minus standard deviation
Showing that the independent sample T test is adopted for comparison among groups; the non-normally distributed data is represented by a median (quartile) [ M (P25, P75)]In this case, the inter-group comparison was performed by the independent sample nonparametric test count data in cases (%) and the inter-group comparison was performed by the X2 test. With P<A difference of 0.05 is statistically significant.
Example 1
1. Volunteer screening
Volunteers were screened for inclusion and exclusion criteria as follows:
inclusion criteria were: (1) compliance with AIS diagnostic criteria [8]; (2) The dialectical type of the traditional Chinese medicine is phlegm stagnation and orifices obstruction syndrome (3) the age is 35-90 years; (4) The patient can see the disease within 72 hours and has no symptom of neurologic deficit after the first stroke or the previous stroke; (5) National Institute of Health Stroke Scale (NIHSS): 4-24 min; (5) And (4) when the patient is admitted, the patient signs an informed consent by himself or family members by improving a Rakin scale (the score of the improved Rakin scale is 0-6, the higher the score is, the more serious the disability is), and the number is more than or equal to 2 (6) (7). The study strictly executes the clinical trial study specification of the hospital, and is executed after being approved by the ethical committee of the hospital.
Exclusion criteria: (1) patients with severe liver and kidney failure (2) are not prescribed to take the medicine, and (3) patients with allergy or severe allergic constitution.
212 AIS patients are selected from the patients who are hospitalized in neurology department of the department of Chinese medicine of Lishui city and have the disease incidence within 72 hours during the period of 1 month to 1 month of 2022 in 2020. The patients in the group were divided into 106 treatment groups and 106 control groups by a random table. Some patients can not insist on taking and quit, and other patients lose visits after discharge, and 193 effective data are finally recovered, wherein 95 patients in a treatment group and 98 patients in a control group. Treatment groups: 60 men and 35 women, the age being 36-90 years. Control group: 59 men and 39 women, age 39-90 years old. The two groups have no statistical significance (P > 0.05) and are comparable in terms of onset age, gender, complications, NIHSS score and TOAST typing (see Table 1).
TABLE 1 comparison of baseline data for two groups of patients
Note: a is chi-square test; b is the Z value; c is a T value; smoking is defined to be more than or equal to 10 cigarettes/day, and smoking lasts for more than 3 years.
2. Medical treatment
Wherein, the patients in the control group are subjected to standard cerebral apoplexy treatments, including platelet aggregation resistance, lipid lowering, plaque stabilizing and the like, and the treatment course is 14 days; the treatment group takes the Chinese medicinal composition decoction of the invention, and the preparation method of the decoction comprises the following steps: 20g of melastoma dodecandrum lour, 9g of pinellia ternate, 6g of exocarpium citri rubrum, 15g of radix curcumae, 12g of pseudo-ginseng, 12g of ligusticum wallichii, 10g of polygala tenuifolia and 12g of rhizoma acori graminei are taken twice a day by adding water and decocting to 400ml, and the treatment course is 14 days.
3. Serum inflammatory factor level determination
Before treatment and after 14 days of treatment, venous blood is drawn with an empty stomach, within 30 minutes after blood drawing, the blood is placed at 3000r/min for centrifugation for 15min, supernatant liquid is taken, and the expression levels of three inflammatory factors, namely TNF-alpha, IL-1 beta and IL-6, are measured by using an enzyme-linked immunosorbent assay monitoring method. The results are shown in Table 2.
TABLE 2 comparison of inflammatory factor levels before and after treatment in two groups of patients
As can be seen from Table 2, the expression levels of TNF-alpha, IL-1 beta and IL-6 in the serum of the two groups of patients were not statistically different before treatment; after 2 weeks of treatment, there was a decrease in serum inflammatory factors in both groups, with the decrease in serum inflammatory factors being greater in the treated group and statistically different from the control group (P < 0.05).
4. Evaluation of therapeutic effects
(1) Integral of Chinese medicine syndrome
Assigning scores to Chinese medicine symptoms of patients according to scoring standard of Chinese medicine new drug clinical research guiding principle, wherein the main contents comprise 7 items of hemiplegia, limb numbness, dysphasia, mouth and tongue deflection, flushed complexion, dysphoria with smothery sensation in chest, palms and soles, weakness, short breath and the like, and the scores are assigned according to the severity of the symptoms, namely none score (0 score), mild score (1 score), moderate score (2 score) and severe score (3 score); the analysis results are shown in Table 3.
TABLE 3 comparison of Chinese medicine syndrome integrals before and after treatment of two groups of patients
(minute)
As can be seen from table 3, there was no statistical difference in the traditional Chinese medicine syndrome scores of the two groups of patients before treatment, and after 1 week of treatment, there was no statistical difference in the two groups of patients although there was a slight difference; after 2 weeks of treatment, the traditional Chinese medicine symptom integral reduction range of the treatment group is greatly different from that of the conventional treatment group, and the difference has statistical significance (P is less than 0.05); the traditional Chinese medicine composition can improve the prognosis of AIS patients.
(2) Modified Rakin Scale score on day 90
Statistics were performed on the scores of the modified Rakin scale at day 90 after treatment in both groups of patients and are shown in FIG. 1.
As can be seen from FIG. 1, the number of independent life functions (0-2 points on the modified Rakin scale) obtained in the treated group was significantly better than that obtained in the control group in the overall score distribution (OR: 1.43% by 95% CL1.04-1.98P-straw bundle of 0.05.
(3) Improved Rakin scale score, NIHSS score and safety index
The modified Rakin scale score, the NIHSS score and various safety indexes of the two groups of patients after two weeks of treatment are counted, and the observation results are shown in a table 4.
TABLE 4 modified Rakin Scale score, NIHSS score, and safety index statistics
Note: a is chi fang inspection; b, the theoretical frequency is less than 5, and a continuity correction value is adopted. seich is symptomatic intracranial hemorrhage.
As can be seen from Table 4, after 14 days of treatment, the number of independent life functions (0-2 points of the modified Rakin scale) and the reduction range of the NIHSS score are both better than those of the control group (P < 0.05); whereas the treatment group did not increase the rate of symptomatic bleeding nor the rate of 90 days death of patients in terms of safety index, there was no statistical difference between the two groups (P > 0.05).
The research of the embodiment discovers that the treatment effect of the traditional Chinese medicine composition provided by the invention on the patients suffering from AIS within 72 hours is better than that of the conventional treatment group, and the tissue damage of brain tissues in anoxia and ischemia can be reduced by inhibiting the release of inflammatory factors such as TNF-alpha, IL-1 beta, IL-6 and the like, so that the nerve function rehabilitation of the patients is promoted, the independent life capacity after stroke is improved, the prognosis of the patients suffering from AIS is finally improved, a positive effect on reduction of disability rate is achieved, and the traditional Chinese medicine composition is worthy of clinical popularization.
Claims (5)
1. A traditional Chinese medicine composition is characterized by comprising, by mass, 15-25 parts of melastoma dodecandrum, 7-12 parts of pinellia ternate, 3-9 parts of exocarpium citri rubrum, 10-20 parts of radix curcumae, 9-15 parts of pseudo-ginseng, 9-15 parts of ligusticum wallichii, 5-15 parts of polygala tenuifolia and 9-15 parts of rhizoma acori graminei.
2. The traditional Chinese medicine composition as claimed in claim 1, which comprises, by mass, 20 parts of melastoma dodecandrum, 9 parts of pinellia ternate, 6 parts of exocarpium citri rubrum, 15 parts of radix curcumae, 12 parts of pseudo-ginseng, 12 parts of ligusticum wallichii, 10 parts of polygala tenuifolia and 12 parts of rhizoma acori graminei.
3. The use of the Chinese medicinal composition of claim 1 or 2 in the preparation of a medicament for the treatment of acute ischemic stroke.
4. The use of the Chinese medicinal composition of claim 3 in the preparation of a medicament for treating acute ischemic stroke, wherein the acute ischemic stroke is phlegm stagnation type acute ischemic stroke.
5. The use of the Chinese medicinal composition of claim 1 or 2 in the preparation of a medicament for the treatment of neuroinflammation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211082031.7A CN115590941B (en) | 2022-09-06 | 2022-09-06 | Traditional Chinese medicine composition and application thereof in preparation of acute ischemic cerebral apoplexy treatment medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211082031.7A CN115590941B (en) | 2022-09-06 | 2022-09-06 | Traditional Chinese medicine composition and application thereof in preparation of acute ischemic cerebral apoplexy treatment medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115590941A true CN115590941A (en) | 2023-01-13 |
| CN115590941B CN115590941B (en) | 2024-01-30 |
Family
ID=84842754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211082031.7A Active CN115590941B (en) | 2022-09-06 | 2022-09-06 | Traditional Chinese medicine composition and application thereof in preparation of acute ischemic cerebral apoplexy treatment medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115590941B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306741A (en) * | 2014-09-26 | 2015-01-28 | 朱晓岩 | A traditional Chinese medicine formula for treating cerebral hemorrhage |
-
2022
- 2022-09-06 CN CN202211082031.7A patent/CN115590941B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306741A (en) * | 2014-09-26 | 2015-01-28 | 朱晓岩 | A traditional Chinese medicine formula for treating cerebral hemorrhage |
Non-Patent Citations (1)
| Title |
|---|
| 史爱菊: "中医辨证论治脑出血脑水肿324例临床观察", 山西中医学院学报, vol. 5, no. 4, pages 29 - 30 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115590941B (en) | 2024-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Serraclara et al. | Hypoglycemic action of an oral fig-leaf decoction in type-I diabetic patients | |
| WO2022021636A1 (en) | Traditional chinese medicine composition for invigorating spleen and activating collaterals, and use thereof | |
| CN104645132A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy, preparation method, traditional Chinese medicine preparation and application of traditional Chinese medicine composition | |
| Panda et al. | Clinical efficacy of herbal Padmapatradi yoga in bronchial asthma (Tamaka Swasa) | |
| Zhou et al. | Tongqiao Huoxue Decoction for the treatment of acute ischemic stroke: A Systematic Review and meta-analysis | |
| CN101584772B (en) | Traditional Chinese medicine for treating diabetes surrounding nerve lesion | |
| CN104826015A (en) | Traditional Chinese medicine with effects of invigorating kidneys and replenishing essence, dispersing blood stasis and dredging collaterals as well as softening veins and eliminating speckles | |
| CN115590941A (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating acute ischemic stroke | |
| CN115054665B (en) | Traditional Chinese medicine composition for treating eczema scrotum | |
| Ou et al. | Efficacy of self-made Hewei decoction for chronic atrophic gastritis and its effect on gastrin and pepsinogen expression levels | |
| Zhang et al. | Efficacy of mudan granule (combined with methylcobalamin) on type 2 diabetic peripheral neuropathy: study protocol for a Double-Blind, randomized, Placebo-Controlled, Parallel-Arm, Multi-Center trial | |
| Sharma et al. | Study the Effectiveness of Lachesis muta 30C in Patients with Essential Hypertension in the Age Group of 20-75 Years | |
| CN109771559A (en) | A kind of Chinese medicine composition and preparation method thereof for treating pulmonary interstitial fibrosis | |
| Wen-jun et al. | Preliminary study on treatment of partial androgen deficiency in aging males with Jingui Shenqi Pill | |
| CN109865128A (en) | A Bilutai is treating and preventing the application in diabetes complicated with cerebral infarction drug | |
| CN109528979A (en) | A kind of composition and its preparation method and application for treating Sjogren syndrome and syndrome of yin deficiency and blood stasis | |
| CN116036212B (en) | Traditional Chinese medicine for treating acute stage of ischemic stroke | |
| CN102895535A (en) | Chinese medicinal preparation for treating chorea minor | |
| CN108969729A (en) | A kind of Chinese medicine composition and its preparation method and application for treating vascular dementia | |
| CN114617939B (en) | Traditional Chinese medicine preparation for treating ischemic cerebral apoplexy | |
| CN111700947B (en) | Traditional Chinese medicine composition for treating ischemic stroke and application thereof | |
| CN108403803B (en) | Chinese medicinal compound preparation for preventing and treating cardiovascular complications of diabetes | |
| CN1463734A (en) | A prepared Chinese medicine for treating diabetes mellitus and method for preparing same | |
| Ding et al. | Influence of tanshinone on coagulation function, hemorheology and neurological function in patients with acute cerebral infarction | |
| CN105194202B (en) | A kind of drug for treating liver-kidney yin deficiency premonitory apoplexy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |